Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Perioperative Vorasidenib and Ivosidenib Remain Effective, Safe in IDH1+ Diffuse Glioma

November 25th 2024

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

FDA Approves Companion Diagnostic for Zanidatamab in HER2+ Biliary Tract Cancer

November 25th 2024

The FDA approved the PATHWAY HER2 (4B5) test to identify patients with HER2-positive biliary tract cancer who are eligible for treatment with zanidatamab.

Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC

November 25th 2024

Capivasertib plus abiraterone and ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer.

FDA Approves Oral Solution of Imatinib for Certain Leukemias, Other Cancers

November 25th 2024

The FDA has approved an oral solution of imatinib for the treatment of certain leukemias and other cancers.

Dr Harding on the FDA Approval of Zanidatamab for HER2+ Biliary Tract Cancer

November 23rd 2024

James J. Harding, MD, discusses the significance of the FDA approval of zanidatamab for pretreated, unresectable or metastatic HER2+ biliary tract cancer.

Long-Term Findings Solidify Role of HER2-Targeted Therapy in Early HER2+ Breast Cancer

November 22nd 2024

Francisco J. Esteva, MD, PhD, highlights various pivotal studies for the treatment of HER2-positive early-stage breast cancer.

Bispecific Antibodies and CAR T-Cell Therapies Continue to Reshape Myeloma Treatment Landscape

November 22nd 2024

Syed Abbas Ali, MBBS, discusses how CAR T-cell therapies and bispecific antibodies have altered treatment in relapsed/refractory multiple myeloma.

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC

November 21st 2024

James J. Harding, MD, discusses how immunotherapy could play a role in earlier stages in hepatocellular carcinoma.

Afami-Cel Shows Durable Persistence and Tumor-Killing Abilities in Synovial Sarcoma

November 21st 2024

Treatment with afami-cel was associated with long-term persistence in the periphery that led to clinical benefit in patients with synovial sarcoma.

EMA Grants PRIME Designation to NX-5948 for R/R CLL/SLL

November 21st 2024

NX-5948 has received PRIME designation from the EMA for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

November 21st 2024

The FDA has accepted a sNDA for darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.

PYX-201 Generates Responses in Pretreated Advanced HNSCC and Other Solid Tumors

November 21st 2024

PYX-201 produced responses in heavily pretreated head and neck squamous cell carcinoma and other solid tumors.

FDA Approves Zanidatamab for Previously Treated, Unresectable or Metastatic HER2+ Biliary Tract Cancer

November 21st 2024

The FDA has granted accelerated approval to zanidatamab for pretreated, advanced HER2-positive biliary tract cancer.

Expanded Indications for CAR T-Cell Therapies Shepherd in New Era of Myeloma Care

November 20th 2024

David R. Oveisi, MD, discusses how the expanded indications for ide-cel and cilta-cel are affecting treatment decision-making in multiple myeloma.

How the Drive to Connect the Oncology Community Built an Educational Podcast Platform: With D. Ross Camidge, MD, PhD; and Rahul Gosain, MD, MBA

November 20th 2024

Drs Camidge and Gosain discuss how Dr Gosain harnessed social media to create a podcast with practice updates for up-and-coming oncology professionals.

CDK4/6 Inhibitors, Targeted Therapies May Expand Their Reach in HR+ Metastatic Breast Cancer

November 19th 2024

Hope S. Rugo, MD, discusses questions regarding CDK4/6 inhibitors and targeted therapies in HR-positive, HER2-negative advanced breast cancer.

Subcutaneous Pembrolizumab Plus Chemo Meets Pharmacokinetic End Points in NSCLC

November 19th 2024

Subcutaneous pembrolizumab plus chemotherapy generated noninferior PK outcomes vs IV pembrolizumab plus chemotherapy in metastatic NSCLC.

FDA Grants Fast Track Designation to ALE.P02 for CLDN1+ Squamous Solid Tumors

November 19th 2024

The FDA granted fast track designation to ALE.P02 for CLDN1-positive squamous solid tumors.

Nogapendekin Alfa Inbakicept Plus BCG Maintains CR Rate in BCG-Unresponsive NMIBC With CIS

November 19th 2024

Nogapendekin alfa inbakicept plus BCG continued to generate complete responses in BCG-unresponsive non–muscle-invasive bladder cancer.

Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma

November 19th 2024

Second-line BTK inhibitors were associated with improved PFS2 and OS2 in late-relapsed mantle cell lymphoma.